

UNIVERSIDADE ESTADUAL PAULISTA
“JÚLIO DE MESQUITA FILHO”
FACULDADE DE CIÊNCIAS FARMACÊUTICAS
CAMPUS ARARAQUARA

LARISSA SBAGLIA CELIBERTO

**INTESTINAL HOMEOSTASIS AND HOST DEFENSE AS PROMOTED BY
COMMENSAL BACTERIA AND THE COLONIC MUCUS LAYER**

ARARAQUARA - SP

2018

UNIVERSIDADE ESTADUAL PAULISTA
“JÚLIO DE MESQUITA FILHO”
FACULDADE DE CIÊNCIAS FARMACÊUTICAS
CAMPUS ARARAQUARA

LARISSA SBAGLIA CELIBERTO

**INTESTINAL HOMEOSTASIS AND HOST DEFENSE AS PROMOTED BY
COMMENSAL BACTERIA AND THE COLONIC MUCUS LAYER**

Tese apresentada à Faculdade de Ciências
Farmacêuticas da Universidade Estadual
Paulista “Júlio de Mesquita Filho”, para a
obtenção do título de Doutora em Alimentos
e Nutrição, área Ciência dos Alimentos.

Orientadora: *Prof^a. Dr^a. Daniela Cardoso Umbelino Cavallini*
Orientador no exterior: *Prof. Dr. Bruce A. Vallance*
Co-orientador: *Dr. Luis Caetano Martha Antunes*

ARARAQUARA - SP
2018

Ficha Catalográfica

Elaborada Por Diretoria Técnica de Biblioteca e Documentação
Faculdade de Ciências Farmacêuticas
UNESP – Campus de Araraquara

C392i

Celiberto, Larissa Sbaglia.

Intestinal homeostasis and host defense as promoted by commensal bacteria and the colonic mucus layer / Larissa Sbaglia Celiberto. – Araraquara, 2018.
170 f. : il.

Tese (Doutorado) – Universidade Estadual Paulista. “Júlio de Mesquita Filho”. Faculdade de Ciências Farmacêuticas. Programa de Pós Graduação em Alimentos e Nutrição. Área de concentração em Ciência de Alimentos.

Orientadora: Daniela Cardoso Umbelino Cavallini.

Orientador no exterior: Bruce A. Vallance.

Coorientador: Luis Caetano Martha Antunes.

1. IBD. 2. Colitis. 3. Microbiota. 4. Microbiota biobank.. 4. Personalized probiotic. 5. Mucus layer. I. Cavallini, Daniela Cardoso Umbelino, orient. II. Vallance, Bruce A., orient. III. Antunes, Luis Caetano Martha, coorient. IV. Título.

CAPES: 50700006

The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, the dissertation entitled:

Intestinal homeostasis and host defense as promoted by commensal bacteria and the colonic mucus layer

submitted by Larissa Sbaglia Celiberto in partial fulfillment of the requirements for

the degree of Doctor of Philosophy

in Food and Nutrition and Experimental Medicine

Examining Committee:

Daniela Cavallini, Food and Nutrition
Co-supervisor

Bruce Vallance, Experimental Medicine
Co-supervisor

Carla Fontana, Pharmaceutical Sciences
Supervisory Committee Member

Xiaonan Lu, Food Science
University Examiner

Ligia Sasaki, Clinical Medicine
University Examiner

Additional Supervisory Committee Members:

Kevan Jacobson, Experimental Medicine
Supervisory Committee Member

Rosana Ferreira, Microbiology and Immunology
Supervisory Committee Member

Abstract

The intestinal tract harbours the largest population of microbes in the human body where they play an important role in promoting the health of their host. If the composition of these microbes is altered, this may lead to dysbiosis that triggers or exacerbates intestinal and extra-intestinal diseases. Probiotics have been investigated as a complementary therapy in dysbiosis-related diseases. However, their effectiveness in treating severe conditions such as Inflammatory Bowel Disease (IBD) is quite variable and have shown controversial results. To address the importance of a personalized probiotic approach to treat intestinal inflammation, we first examined the effect of personalized bacteria using a model of chemical induced colitis. The animals that received commensals isolated from their own feces were more protected against inflammation as they showed reduced signs of colitis, less histological damage and lower levels of inflammatory markers as compared to mice given a commercial probiotic strain. Next, the role of the intestinal mucin Muc2 and the Core-1 enzyme that glycosylates it were explored using the *Citrobacter rodentium* model of infectious colitis. The intestinal mucus layer is the first line of defense in the intestine and is largely composed of the secreted mucin Muc2. Since almost all enteric bacteria must cross the overlying mucus layer to infect the host, the mucus-enteric bacterial interactions provide fundamental knowledge about infectious diseases as well as inflammatory conditions linked to dysbiosis (e.g. IBD). Specifically, we compared *C. rodentium* susceptibility by infecting WT, *Muc2*^{-/-}, core 3 (*C3GnT*)^{-/-}, core -1 (*Clgalt1*)^{-/-}, and *Clgalt1*^{ff} mice. While *C3GnT*^{-/-} mice showed a very similar phenotype to WT mice with only mild inflammation, complete absence of Muc2 or just core 1 derived O-glycans resulted in significantly higher histological damage, barrier disruption, and increased pathogen burdens. Interestingly, the supplementation of tributyrin

protected mice against infection resulting in less histological damage and lower *C. rodentium* colonization as compared to control groups. These studies highlight a novel personalized therapy that may be considered relevant to diseases affected by dysbiosis as well as the key role of Muc2 and its core 1 glycosylation in host defense against enteric infections.

Keywords: IBD; colitis, microbiota; microbiota biobank, personalized probiotic, mucus layer

Lay Summary

The human gut harbors several types of bacteria that play an important role in the well-being of their host. The intestinal mucus layer is also important for intestinal health, since it acts as a physical barrier that prevents bacteria and food products from escaping the gut and causing inflammation. Using an animal model of intestinal inflammation, I discovered that beneficial bacteria isolated from the host are more effective in protecting mice against intestinal damage as compared to probiotic bacteria available on the market. Further, using an animal model of a gut bacterial infection, I tested the impact of the mucus layer on protection against intestinal inflammation. I found that the mucin Muc2 and one of its sugar compounds protect mice against intestinal damage caused by enteric bacteria. These findings have implications for both Inflammatory Bowel Disease and people with gut infections– and could help develop new and effective complementary treatments.

Preface

Chapter 2

I designed and conducted the majority of the studies reported in this chapter, analyzed the data, prepared all of the figures and wrote the manuscript under the supervision of Dr. Daniela C.U. Cavallini and Dr. Bruce A. Vallance. Dr. Elizeu A. Rossi provided input to the study design. Ms. Roseli A. Pinto assisted in microbiological tests and performed the antibiotic susceptibility test leading to Supplemental Figure A1.

A version of this chapter has been published in the journal *Nutrients* as: Celiberto LS, Pinto RA, Rossi EA, Vallance BA, Cavallini DCU. Isolation and characterization of potentially probiotic bacterial strains from mice: proof of concept for personalized probiotics. *Nutrients* **2018**, *10*(11), 1684; doi: 10.3390/nu10111684 (Gut Microbiome and Human Health).

Ethics approval was required for this research and was obtained from the Sao Paulo State University Animal Care Committee certificate number 34/2014 and the University of British Columbia Animal Care Committee certificate number A15-0206.

Chapter 3

I conducted the majority of the studies reported in this chapter, analyzed the data, prepared all of the figures and wrote the manuscript under the supervision of Dr. Bruce A. Vallance and Dr. Daniela CU Cavallini. Dr. HT Law, Dr. Genelle Healey, Mr. Justin HY Chan and Ms. Qiaochu Liang assisted with study design, animal experimentation, histopathological scores and provided useful insights regarding the results discussion. Dr. Kiran Bhullar performed experiments with *C3GnT*^{-/-} mice leading to figure 3.4 IEC *Clgalt1*^{-/-} and *C3GnT*^{-/-} mice were generated and kindly provided by Dr. Lijun Xia, University of Oklahoma. A version of this chapter will be submitted for publication.

Ethics approval was required for this research and was obtained from the University of British Columbia Animal Care Committee certificate number A15-0206.

Table of Contents

Abstract.....	ii
Lay Summary	iv
Preface.....	v
Table of Contents	vii
List of Tables	xi
List of Figures.....	xii
List of Symbols	xiv
Acknowledgements	xix
Dedication	xxi
Chapter 1: Literature review	1
1.1 The human microbiome	1
1.2 The human gastrointestinal tract.....	6
1.3 The intestinal microbiota	10
1.4 Gut microbiome in health and disease	16
1.5 Animal models of intestinal inflammation	18
1.6 Modulation of the gut microbiome through probiotics.....	22
1.7 The intestinal mucus layer and its role in host defense	27
1.7.1 MUC2 structure and synthesis	28
1.7.2 MUC2 glycosylation.....	30
1.7.3 Mucus and the gut microbiome.....	32
1.8 Research hypothesis and objectives.....	37

vii

Chapter 2: Isolation and characterization of potentially probiotic bacterial strains from

mice: proof of concept for personalized probiotics.....39

2.1	Introduction.....	39
2.2	Experimental procedures	43
2.2.1	Mice	43
2.2.2	Isolation of commensal bacteria strains.....	43
2.2.3	Preliminary identification	44
2.2.4	Genera confirmation	44
2.2.5	Evaluation of survival in simulated gastrointestinal conditions	45
2.2.6	Antibiotic susceptibility test	46
2.2.7	Dextran sodium sulfate (DSS)-induced colitis experiment	48
2.2.8	Tissue collection	50
2.2.9	Histopathological scoring	50
2.2.10	RNA extractions and quantitative real-time PCR.....	50
2.2.11	Myeloperoxidase (MPO) and malondialdehyde (MDA) activity	51
2.2.12	Statistical analysis.....	52
2.3	Results.....	53
2.3.1	Isolation and genera confirmation of the strains.....	53
2.3.2	<i>In vitro</i> tests demonstrate a potential probiotic effect of the isolated strains.....	54
2.3.3	Personalized commensal strains protect mice against acute dextran sodium sulfate-induced colitis	58
2.3.4	Personalized probiotic therapy positively modulates the host immune response during DSS-colitis.....	61

2.4	Discussion	65
Chapter 3: Role of the mucin (Muc)2 and its glycosylation in controlling susceptibility to		
<i>Citrobacter rodentium</i> infection.....		73
3.1	Introduction.....	73
3.2	Experimental procedures	77
3.2.1	Mice	77
3.2.2	Bacterial strains, <i>Citrobacter rodentium</i> infection and tributyrin supplementation	77
3.2.3	Tissue collection	78
3.2.4	Histopathological scoring	78
3.2.5	Short chain fatty acid analysis	79
3.2.6	Statistical analysis.....	80
3.3	Results.....	81
3.3.1	<i>Muc2</i> ^{-/-} mice show increased susceptibility to <i>C. rodentium</i> infection	81
3.3.2	C3GnT ^{-/-} mice show modest susceptibility to <i>C. rodentium</i> similar to WT mice	82
3.3.3	<i>Clgalt1</i> (IEC) ^{-/-} mice develop exaggerated colitis during <i>C. rodentium</i> infection	84
3.3.4	<i>Clgalt1</i> ^{-/-} mice carry high <i>C. rodentium</i> intestinal burdens similar to <i>Muc2</i> ^{-/-}	87
3.3.5	<i>Muc2</i> ^{-/-} mice exhibit lower stool concentrations of propionic and butyric acids under baseline condition	91
3.3.6	Tributyrin supplementation ameliorates damage caused by <i>C. rodentium</i> infection	93
3.4	Discussion	97

Chapter 4: Conclusions	102
4.1 The big picture: potential application of the research findings.....	102
4.2 Future directions	105
4.3 Final remarks	107
References	109
Appendix A.....	145

List of Tables

Table 2.1 Population of the strains exposed to stimulated gastrointestinal solutions.....	55
Table 2.2 Zone diameter values to indicate susceptible, intermediate and resistance breakpoints of each strain	57

List of Figures

Figure 1.1 Schematic of the human colon showing the full thickness of the intestinal wall.....	9
Figure 1.2 Histological analysis of damage caused in colonic tissues by DSS-colitis	20
Figure 1.3 Histological damage caused to murine colonic tissues by <i>C. rodentium</i> infection	22
Figure 1.4 Domain structure and biosynthesis of MUC2 mucin	30
Figure 1.5 The biosynthesis of mucin type O-glycans	32
Figure 1.6 Intestinal homeostasis as promoted by SCFA	36
Figure 2.1 Schematic image of the probiotic personalization procedure.....	47
Figure 2.2 Description of the groups used in the DSS experiment.....	48
Figure 2.3 DSS experiment timeline.....	49
Figure 2.4 PCR products of isolated commensal bacteria	54
Figure 2.5 Disease activity index (DAI) during the course of DSS-induced colitis.....	59
Figure 2.6 Representative photomicrographs of mouse distal colon sections with haematoxylin and eosin	60
Figure 2.7 Histopathology score	61
Figure 2.8 Pro-inflammatory and anti-inflammatory cytokines	63
Figure 2.9 Colonic expression of MPO and MDA	64
Figure 3.1 <i>Muc2</i> ^{-/-} mice exhibit dramatic susceptibility to <i>C. rodentium</i> -induced morbidity and mortality	81
Figure 3.2 Macroscopic image of heightened mucosal damage in <i>Muc2</i> ^{-/-} as compared to WT mice.....	82
Figure 3.3 <i>C3GnT</i> ^{-/-} mice exhibit similar <i>C. rodentium</i> susceptibility to WT mice	83

Figure 3.4 C3GnT ^{-/-} mice exhibit modest tissue damage similar to WT mice	84
Figure 3.5 <i>Muc2</i> ^{-/-} and <i>Clgalt</i> ^{-/-} mice exhibit similar <i>C. rodentium</i> susceptibility	86
Figure 3.6 <i>Muc2</i> ^{-/-} and <i>Clgalt1</i> ^{-/-} mice carry heavier intestinal pathogen burdens	88
Figure 3.7 <i>Muc2</i> ^{-/-} and <i>Clgalt1</i> ^{-/-} mice display similar susceptibility to <i>C. rodentium</i> infection .	90
Figure 3.8 <i>Muc2</i> ^{-/-} mice display lower levels of propionic and butyric acids under baseline condition	92
Figure 3.9 <i>Muc2</i> ^{-/-} and <i>Clgalt</i> ^{-/-} mice display lower <i>C. rodentium</i> susceptibility with TB supplementation	94
Figure 3.10 <i>Clgalt1</i> ^{-/-} mice carry heavier intestinal pathogen burdens.....	95
Figure 3.11 <i>Muc2</i> ^{-/-} and <i>Clgalt1</i> ^{-/-} display less severe colitis with TB supplementation.....	96

List of symbols and abbreviations

α	alpha
β	beta
γ	gamma
κ	kappa
μ	micro
$^{\circ}$	degree
C	Celsius
<	less than
$\leq$	less than or equal to
>	greater than
+	positive
$\pm$	plus or minus
-/-	deficient
5-HT	5-hydroxytryptamine (serotonin)
ADP	adenosine diphosphate
A/E	attaching and effacing
AMP	antimicrobial peptide
ATP	adenosine triphosphate
CFU	colony forming units
CTRL	control
DAI	disease activity index

DAPI	4',6-diamidino-2-phenylindole
DC	dendritic cell
DNA	deoxyribose nucleic acid
DNBS	2,4-dinitrobenzenesulfonic acid
DSS	dextran sodium sulfate
EHEC	Enterohemorrhagic <i>Escherichia coli</i>
e.g.	<i>exempli gratia</i> (for example)
ER	endoplasmic reticulum
EPEC	Enteropathogenic <i>Escherichia coli</i>
F/B	<i>Firmicutes/Bacteroidetes</i>
FITC	fluorescein isothiocyanate
FOS	fructooligosaccharide
g	gram
GI	Gastrointestinal tract
GF	germ free
GL	glycerol
GOS	galactooligosaccharide
GPR	G protein coupled receptor
HIV	Human Immunodeficiency virus
HMP	Human Microbiome Project
IAP	intestinal alkaline phosphatase
IBD	Inflammatory Bowel Disease
IBS	irritable bowel syndrome

i.e.	<i>id est</i> (that is)
IEC	intestinal epithelial cell
IEC-C1galt1-/-	IEC specific deletion of core 1-derived O-glycans
IEL	intraepithelial lymphocyte
IFN	interferon
Ig	immunoglobulin
IL	interleukin
ITS	internal transcribed spacer
L	litre
LEE	locus of enterocyte effacement
LGG	<i>Lactobacillus rhamnosus</i> GG
LI	large intestine
LPS	lipopolysaccharide
m	meters
M cells	microfold cells
MAPK	mitogen activated protein kinase
MDA	malonaldehyde
MetaHIT	Metagenomics of the Human Intestinal Tract.
MLN	mesenteric lymph nodes
MPO	myeloperoxidase
Muc2	mucin 2
NGS	next generation sequence
NIH	National Institute of Health

NOD	nucleotide-binding oligomerization domain
NF- κ B	Nuclear factor kappa-B
pi	post infection
PP	personalized probiotics
PTS	Proline- threonine -serine
qPCR	quantitative PCR
Reg III γ	regenerating islet-derived protein 3 gamma
Relm β	resistin like molecule beta
RNA	ribonucleic acid
rRNA	ribosomal RNA
ROS	reactive oxygen species
SCFA	short chain fatty acid
SD	standard deviation
SEM	standard error mean
SI	small intestine
S. Typhimurium	<i>Salmonella</i> enterica serovar Typhimurium
T3SS	type 3 secretion system
TB	tributylin
TCR	T cell receptor
TFF3	trefoil like factor 3
TGF β	transforming growth factor beta
Th	T helper
Tir	translocated intimin receptor

TJ	tight junction
TLR	toll like receptor
TNBS	2,4,6-trinitrobenzene sulphonic acid
TNF	tumor necrosis factor
Treg	T regulatory
Wnt	Wingless/Integrated
WT	wildtype
ZO	zonula occludens

Acknowledgements

I am very fortunate to have received unreserved support from many exceptional individuals during my PhD studies. I am forever grateful to my graduate co-supervisors, Dr. Daniela Cavallini and Dr. Bruce Vallance for their patience, kindness and guidance throughout my tenure as a PhD student. Thank you both for providing me with opportunities to learn different laboratory techniques and experimental models. I also appreciate all the support I had during the Joint degree set up between the two universities. Thank you Daniela for showing me the wonderful world of ‘good bacteria’ and all the amazing applications of probiotics. Also, thank you for all your support with my crazy and ambitious ideas with this international collaboration. I could not have accomplished this without you. Bruce - Thank you for teaching me so much about gut disorders and how to apply my previous knowledge in all these different models. Thank you for teaching me how to “tell a story” through research and scientific writing and for all the incredible support during my thesis writing. I cannot describe how grateful I am for the opportunity to work in your lab in Canada. I also thank my graduate supervisory committee Dr. Carla Fontana and Dr. Kevan Jacobson, for inspiring me with their own research and for providing me with guidance and valuable insights.

I owe a special thank you to Dr. Elizeu Antonio Rossi for providing me with the idea from one of my PhD projects. I also thank Dr. Caetano Antunes for introducing me to Dr. Vallance and for all the support during my PhD.

To all the past and current members of the Cavallini and Vallance laboratories, I thank all of them for creating a great working environment that encourages collaboration and supports new ideas. I thank Ms. Roseli Pinto, Ms. Josiane Canaan, Ms. Caixia Ma, Ms. Tina Huang and Ms. Mimi Kuan

for teaching me many laboratory techniques and always being ready to lend a helping hand. To Olivia Zordão, thank you for all the hard work and friendship during long animal experiments. Thank you to my colleagues who have provided friendship, encouragement and thoughtful suggestions through all the ups and downs of graduate school, especially Juliana Marchesin, Juliana Witzler, Ana Luiza Duque and Fernanda Bianchi. Thank you for my amazing “Core 1 team” Dr. Genelle Healey, Dr. HT Law, Justin YH Chan and Qiaochu Liang. It is truly a pleasure working with you everyday in the lab. A special thank you goes to my wonderful friends in Canada Dr. Joannie Allaire, Franzi Graef, Else Bosman, Shauna Crowley and Vivian Han. Thank you girls for kindly welcoming me into Vancouver and for all the science and life contributions you have made in my life. You are all truly an inspiration!

I offer my enduring gratitude to the faculty and staff at UNESP and UBC, who have helped me with a lot of paper work and orientation during my studies. I owe particular thanks to Ms. Claudia Molina, Ms. Jennifer Fletcher and everyone from the Dean’s department from both universities for all the work during the Joint PhD set-up agreement.

Thank you to my husband Moises for endless support, unconditional love, and for always standing by me through all the difficult times of graduate student life. With you, life is filled with positivity and happiness. And finally, I would like to express my deepest gratitude to my parents and my sister who have provided nothing but love and encouragement throughout my life. Thank mom and dad for your unconditional support during my education. I could never describe in words how fortunate I am to have you all in my life.

I would like to acknowledge Sao Paulo Research Foundation (FAPESP) for the Doctoral and the international internship (BEPE) scholarships. I also thank Dr. Bruce Vallance for providing my stipend during my second year of studies in Canada.

To my mom and dad, for always loving and supporting me.

References

1. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. *Cell* [Internet]. NIH Public Access; 2012 Mar 16 [cited 2018 Jul 27];148(6):1258–70. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22424233>
2. Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. *Cell* [Internet]. Elsevier; 2016 Jan 28 [cited 2018 Aug 14];164(3):337–40. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0092867416000532>
3. Wang B, Yao M, Lv L, Ling Z, Li L. The Human Microbiota in Health and Disease. *Engineering* [Internet]. Elsevier; 2017 Feb 1 [cited 2018 Jul 25];3(1):71–82. Available from: <https://www.sciencedirect.com/science/article/pii/S2095809917301492#bib7>
4. Consortium THMP, Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, et al. Structure, function and diversity of the healthy human microbiome. *Nature* [Internet]. Nature Publishing Group; 2012 Jun 14 [cited 2018 Jul 25];486(7402):207–14. Available from: <http://www.nature.com/articles/nature11234>
5. Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. *BMJ* [Internet]. British Medical Journal Publishing Group; 2017 Mar 15 [cited 2018 Jul 25];356:j831. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28298355>
6. Arnold JW, Roach J, Azcarate-Peril MA. Emerging Technologies for Gut Microbiome Research. *Trends Microbiol* [Internet]. NIH Public Access; 2016 [cited 2018 Aug 1];24(11):887–901. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27426971>
7. Laupland KB, Valiquette L. The changing culture of the microbiology laboratory. *Can J Infect Dis Med Microbiol = J Can des Mal Infect la Microbiol medicale* [Internet]. Hindawi Limited; 2013 [cited 2018 Jul 27];24(3):125–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24421822>
8. NIH HMP Working Group TNHW, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, et al. The NIH Human Microbiome Project. *Genome Res* [Internet]. Cold Spring Harbor Laboratory Press; 2009 Dec [cited 2018 Jul 25];19(12):2317–23. Available from:

- <http://www.ncbi.nlm.nih.gov/pubmed/19819907>
9. Human Microbiome Project Consortium BA, Nelson KE, Pop M, Creasy HH, Giglio MG, Huttenhower C, et al. A framework for human microbiome research. *Nature* [Internet]. NIH Public Access; 2012 Jun 13 [cited 2018 Jul 27];486(7402):215–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22699610>
 10. Gilbert JA, Dupont CL. Microbial Metagenomics: Beyond the Genome. *Ann Rev Mar Sci* [Internet]. 2011 Jan 15 [cited 2018 Jul 27];3(1):347–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21329209>
 11. Oulas A, Pavloudi C, Polymenakou P, Pavlopoulos GA, Papanikolaou N, Kotoulas G, et al. Metagenomics: tools and insights for analyzing next-generation sequencing data derived from biodiversity studies. *Bioinform Biol Insights* [Internet]. SAGE Publications; 2015 [cited 2018 Aug 1];9:75–88. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25983555>
 12. Jovel J, Patterson J, Wang W, Hotte N, O’Keefe S, Mitchel T, et al. Characterization of the Gut Microbiome Using 16S or Shotgun Metagenomics. *Front Microbiol* [Internet]. Frontiers Media SA; 2016 [cited 2018 Aug 1];7:459. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27148170>
 13. Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. *Nutr Rev* [Internet]. NIH Public Access; 2012 Aug [cited 2018 Jul 25];70 Suppl 1(Suppl 1):S38-44. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22861806>
 14. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med* [Internet]. BioMed Central; 2016 Dec 27 [cited 2018 Aug 1];8(1):51. Available from: <http://genomemedicine.biomedcentral.com/articles/10.1186/s13073-016-0307-y>
 15. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature* [Internet]. NIH Public Access; 2012 Sep 13 [cited 2018 Apr 20];489(7415):220–30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22972295>
 16. Consortium THMP, Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, et al. Structure, function and diversity of the healthy human microbiome. *Nature* [Internet]. Nature Publishing Group; 2012 Jun 14 [cited 2018 Jul 27];486(7402):207–14. Available

- from: <http://www.nature.com/articles/nature11234>
17. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* [Internet]. 2010 Mar 4 [cited 2018 Aug 1];464(7285):59–65. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20203603>
 18. Belda-Ferre P, Alcaraz LD, Cabrera-Rubio R, Romero H, Simón-Soro A, Pignatelli M, et al. The oral metagenome in health and disease. *ISME J* [Internet]. Nature Publishing Group; 2012 Jan [cited 2018 Aug 7];6(1):46–56. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21716308>
 19. Duran-Pinedo AE, Chen T, Teles R, Starr JR, Wang X, Krishnan K, et al. Community-wide transcriptome of the oral microbiome in subjects with and without periodontitis. *ISME J* [Internet]. Nature Publishing Group; 2014 Aug [cited 2018 Aug 7];8(8):1659–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24599074>
 20. Kianoush N, Adler CJ, Nguyen K-AT, Browne G V, Simonian M, Hunter N. Bacterial profile of dentine caries and the impact of pH on bacterial population diversity. *PLoS One* [Internet]. Public Library of Science; 2014 [cited 2018 Aug 7];9(3):e92940. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24675997>
 21. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. *Science* [Internet]. American Association for the Advancement of Science; 2009 May 29 [cited 2018 Aug 7];324(5931):1190–2. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19478181>
 22. Chen YE, Fischbach MA, Belkaid Y. Skin microbiota-host interactions. *Nature* [Internet]. NIH Public Access; 2018 [cited 2018 Aug 7];553(7689):427–36. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29364286>
 23. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* [Internet]. National Academy of Sciences; 2011 Mar 15 [cited 2018 Aug 7];108 Suppl 1(Supplement 1):4680–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20534435>
 24. Fettweis JM, Brooks JP, Serrano MG, Sheth NU, Girerd PH, Edwards DJ, et al. Differences in vaginal microbiome in African American women versus women of

- European ancestry. *Microbiology* [Internet]. Microbiology Society; 2014 Oct [cited 2018 Aug 7];160(Pt 10):2272–82. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25073854>
25. Celiberto LS, Graef FA, Healey GR, Bosman ES, Jacobson K, Sly LM, et al. Inflammatory Bowel Disease and Immunonutrition: Novel Therapeutic Approaches Through Modulation of Diet and the Gut Microbiome. *Immunology* [Internet]. 2018 Apr 25 [cited 2018 Apr 30]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29693729>
 26. Saffrey MJ. Aging of the mammalian gastrointestinal tract: a complex organ system. *Age (Omaha)* [Internet]. Springer Netherlands; 2014 Jun 20 [cited 2018 May 15];36(3):9603. Available from: <http://link.springer.com/10.1007/s11357-013-9603-2>
 27. Bellmann S, Carlander D, Fasano A, Momcilovic D, Scimeca JA, Waldman WJ, et al. Mammalian gastrointestinal tract parameters modulating the integrity, surface properties, and absorption of food-relevant nanomaterials. *Wiley Interdiscip Rev Nanomedicine Nanobiotechnology* [Internet]. 2015 Sep [cited 2018 May 4];7(5):609–22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25641962>
 28. Thomson A, Shaffer E. First Principles of Gastroenterology [Internet]. [cited 2018 May 17]. Available from: <https://www.cag-acg.org/publications/first-principles-of-gastroenterology>
 29. Fawley J, Gourlay DM. Intestinal alkaline phosphatase: a summary of its role in clinical disease. *J Surg Res* [Internet]. NIH Public Access; 2016 May 1 [cited 2018 May 17];202(1):225–34. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27083970>
 30. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. *Nat Rev Immunol* [Internet]. Nature Publishing Group; 2014 Oct 19 [cited 2018 May 18];14(10):667–85. Available from: <http://www.nature.com/articles/nri3738>
 31. Laurin M, Everett M Lou, Parker W. The Cecal Appendix: One More Immune Component With a Function Disturbed By Post-Industrial Culture. *Anat Rec Adv Integr Anat Evol Biol* [Internet]. 2011 Apr [cited 2018 May 18];294(4):567–79. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21370495>
 32. Young B (Pathologist), O’Dowd G, Woodford P. *Wheater’s functional histology : a text and colour atlas*. 433 p.

33. Jejunum's Function in the Small Intestine and Digestive System: [Internet]. [cited 2018 Oct 16]. Available from: <https://www.healthpages.org/anatomy-function/anatomy-function-digestive-system/>
34. F F M Allaire DI, Crowley SM, Law HT, Chang S-Y, Ko H-J, Vallance BA. The Intestinal Epithelium: Central Coordinator of Mucosal Immunity. Trends Immunol [Internet]. 2018 [cited 2018 May 4]; Available from: [https://www.cell.com/trends/immunology/pdf/S1471-4906\(18\)30068-1.pdf](https://www.cell.com/trends/immunology/pdf/S1471-4906(18)30068-1.pdf)
35. Crosnier C, Stamataki D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet [Internet]. Nature Publishing Group; 2006 May 1 [cited 2018 Aug 7];7(5):349–59. Available from: <http://www.nature.com/articles/nrg1840>
36. Hao W-L, Lee Y-K. Microflora of the Gastrointestinal Tract: A Review. In: Public Health Microbiology [Internet]. New Jersey: Humana Press; 2004 [cited 2018 May 15]. p. 491–502. Available from: <http://link.springer.com/10.1385/1-59259-766-1:491>
37. Cénit MC, Matzaraki V, Tigchelaar EF, Zhernakova A. Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta - Mol Basis Dis [Internet]. Elsevier B.V.; 2014 Oct;1842(10):1981–92. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0925443914001513>
38. Johansson ME V., Hansson GC. Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol [Internet]. Nature Publishing Group; 2016 Oct 8 [cited 2018 May 17];16(10):639–49. Available from: <http://www.nature.com/articles/nri.2016.88>
39. Allaire JM, Morampudi V, Crowley SM, Stahl M, Yu H, Bhullar K, et al. Frontline defenders: goblet cell mediators dictate host-microbe interactions in the intestinal tract during health and disease. Am J Physiol Liver Physiol [Internet]. 2018 Mar 1 [cited 2018 Aug 8];314(3):G360–77. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29122749>
40. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature [Internet]. 2011 Jan 27 [cited 2018 Jul 18];469(7331):543–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21270894>
41. Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, et al. Interaction of

- probiotic *Lactobacillus* and *Bifidobacterium* strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production. *Int J Food Microbiol* [Internet]. 2008 Jul 31 [cited 2018 Jul 18];125(3):286–92. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18524406>
42. Yatsunenkov T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. *Nature* [Internet]. 2012 Jun 9 [cited 2018 Jul 19];486(7402):222–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22699611>
 43. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol* [Internet]. 2013 Apr [cited 2018 Jul 19];24(2):160–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22940212>
 44. Furusawa Y, Obata Y, Fukuda S, Endo T a, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*. 2013;504(7480):446–50.
 45. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function. *Science* (80-) [Internet]. 2012 Apr 27 [cited 2018 Jul 19];336(6080):489–93. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22442383>
 46. Dominguez-Bello MG, Blaser MJ. The Human Microbiota as a Marker for Migrations of Individuals and Populations. *Annu Rev Anthropol* [Internet]. Annual Reviews ; 2011 Oct 21 [cited 2018 Aug 7];40(1):451–74. Available from: <http://www.annualreviews.org/doi/10.1146/annurev-anthro-081309-145711>
 47. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. *Nature* [Internet]. 2006 Dec 21 [cited 2018 Apr 20];444(7122):1022–3. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17183309>
 48. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the Human Intestinal Microbial Flora. *Science* (80-) [Internet]. 2005 Jun 10 [cited 2018 Aug 22];308(5728):1635–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15831718>

49. Martin R, Nauta AJ, Amor K Ben, Knippels LMJ, Knol J, Garssen J. Early life : gut microbiota and immune development in infancy. 2010;1(December):367–82.
50. Ley RE, Turnbaugh PJ, Klein S, Gordon JL. Microbial ecology: Human gut microbes associated with obesity. *Nature*. 2006;444:1022–3.
51. Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna BS. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. *Indian J Med Res [Internet]*. Wolters Kluwer -- Medknow Publications; 2015 Jul [cited 2018 Aug 22];142(1):23–32. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26261163>
52. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature [Internet]*. Nature Publishing Group; 2011 May 12 [cited 2018 Aug 16];473(7346):174–80. Available from: <http://www.nature.com/doi/10.1038/nature09944>
53. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Doré J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiol [Internet]*. BioMed Central; 2009 Jun 9 [cited 2018 Aug 22];9(1):123. Available from: <http://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-9-123>
54. Woodmansey EJ. Intestinal bacteria and ageing. *J Appl Microbiol [Internet]*. 2007 May [cited 2018 Aug 22];102(5):1178–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17448153>
55. Hébuterne X. Gut changes attributed to ageing: effects on intestinal microflora. *Curr Opin Clin Nutr Metab Care [Internet]*. 2003 Jan [cited 2018 Aug 22];6(1):49–54. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12496680>
56. Kirjavainen* P V., Kalliomäki M, Salminen SJ, Isolauri E. Postnatal effects of obstetrical epidural anesthesia on allergic sensitization. *Allergy [Internet]*. Wiley/Blackwell (10.1111); 2007 Jan 1 [cited 2018 Aug 22];62(1):88–9. Available from: <http://doi.wiley.com/10.1111/j.1398-9995.2006.01259.x>
57. Heikkilä MP, Saris PEJ. Inhibition of *Staphylococcus aureus* by the commensal bacteria of human milk. *J Appl Microbiol [Internet]*. 2003 [cited 2018 Aug 22];95(3):471–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12911694>

58. Dominguez-bello MG, Costello EK, Contreras M, Magris M, Hidalgo G. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. 2010;107(26):11971–5.
59. Martín R, Heilig GHJ, Zoetendal EG, Smidt H, Rodríguez JM. Diversity of the *Lactobacillus* group in breast milk and vagina of healthy women and potential role in the colonization of the infant gut. *J Appl Microbiol* [Internet]. Wiley/Blackwell (10.1111); 2007 Jul 20 [cited 2018 Aug 22];103(6):2638–44. Available from: <http://doi.wiley.com/10.1111/j.1365-2672.2007.03497.x>
60. Liepke C, Adermann K, Raida M, Mägert H-J, Forssmann W-G, Zucht H-D. Human milk provides peptides highly stimulating the growth of bifidobacteria. *Eur J Biochem* [Internet]. Wiley/Blackwell (10.1111); 2002 Feb 1 [cited 2018 Aug 23];269(2):712–8. Available from: <http://doi.wiley.com/10.1046/j.0014-2956.2001.02712.x>
61. Dethlefsen L, Huse S, Sogin ML, Relman DA. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing. Eisen JA, editor. *PLoS Biol* [Internet]. 2008 Nov 18 [cited 2018 Aug 22];6(11):e280. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19018661>
62. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. *ISME J* [Internet]. 2007 May 1 [cited 2018 Aug 23];1(1):56–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18043614>
63. Löfmark S, Jernberg C, Billström H, Andersson DI, Edlund C. Restored fitness leads to long-term persistence of resistant *Bacteroides* strains in the human intestine. *Anaerobe* [Internet]. 2008 Jun [cited 2018 Aug 23];14(3):157–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18434218>
64. Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant *Enterococcus* species after antibiotics to eradicate *Helicobacter pylori*. *Ann Intern Med* [Internet]. 2003 Sep 16 [cited 2018 Aug 23];139(6):483–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/13679325>
65. Bernalier-Donadille A. Fermentative metabolism by the human gut microbiota. *Gastroentérologie Clin Biol* [Internet]. Elsevier Masson; 2010 Sep 1 [cited 2018 Oct

- 10];34:S16–22. Available from:
<https://www.sciencedirect.com/science/article/pii/S0399832010700166>
66. Briefel RR, Johnson CL. Secular trends in dietary intake in the United States. *Annu Rev Nutr.* 2004;24(1):401–31.
 67. Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi JC, Verschoor CP, et al. Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction. *Cell Host Microbe* [Internet]. 2017 Apr 12 [cited 2018 Jan 6];21(4):455–466.e4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28407483>
 68. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. *Proc Natl Acad Sci* [Internet]. 2005 Aug 2 [cited 2018 Oct 10];102(31):11070–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16033867>
 69. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* [Internet]. 2006 Dec 21 [cited 2018 May 1];444(7122):1027–131. Available from:
<http://www.nature.com/doifinder/10.1038/nature05414>
 70. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome. *Cell Host Microbe* [Internet]. 2008 Apr 17 [cited 2018 Apr 20];3(4):213–23. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/18407065>
 71. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* [Internet]. NIH Public Access; 2009 Nov 11 [cited 2018 Oct 10];1(6):6ra14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20368178>
 72. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. *Diabetes* [Internet]. 2007 Jul 1 [cited 2018 Oct 10];56(7):1761–72. Available from:
<http://diabetes.diabetesjournals.org/cgi/doi/10.2337/db06-1491>
 73. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. *Diabetologia* [Internet]. 2007

- Oct 1 [cited 2018 Oct 10];50(11):2374–83. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/17823788>
74. Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM. Dietary modulation of clostridial cluster XIVa gut bacteria (*Roseburia* spp.) by chitin–glucan fiber improves host metabolic alterations induced by high-fat diet in mice. *J Nutr Biochem* [Internet]. 2012 Jan [cited 2018 Oct 10];23(1):51–9. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/21411304>
 75. Nava GM, Carbonero F, Ou J, Benefiel AC, O’Keefe SJ, Gaskins HR. Hydrogenotrophic microbiota distinguish native Africans from African and European Americans. *Environ Microbiol Rep* [Internet]. 2012 Jun [cited 2018 Oct 10];4(3):307–15. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/23760794>
 76. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, et al. Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes. *Science* (80-) [Internet]. 2011 Oct 7 [cited 2018 Oct 10];334(6052):105–8. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/21885731>
 77. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. *Nutrients* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2014 Dec 24 [cited 2018 Oct 10];7(1):17–44. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/25545101>
 78. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. *FEMS Microbiol Lett* [Internet]. 2009 May [cited 2018 Oct 10];294(1):1–8. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/19222573>
 79. Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. *Gut* [Internet]. 2000 Sep [cited 2018 Oct 10];47(3):397–403. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10940278>
 80. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? *World J Gastroenterol* [Internet]. 2011 Feb 7 [cited 2018 Oct 10];17(5):557. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21350704>

81. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* [Internet]. Nature Publishing Group; 2017 Jun 14 [cited 2018 Jul 11];14(8):491. Available from: <http://www.nature.com/doifinder/10.1038/nrgastro.2017.75>
82. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* [Internet]. Nature Publishing Group; 2014 Aug 10 [cited 2018 Jul 11];11(8):506–14. Available from: <http://www.nature.com/articles/nrgastro.2014.66>
83. Ontario L. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food Guidelines for the Evaluation of Probiotics in Food Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. [cited 2018 Apr 21]; Available from: http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
84. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature*. Nature Research; 2014 Sep;514(7521):181.
85. Krishnan S, Alden N, Lee K. Pathways and functions of gut microbiota metabolism impacting host physiology. *Curr Opin Biotechnol* [Internet]. NIH Public Access; 2015 Dec [cited 2018 Jul 10];36:137–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26340103>
86. Kobozev I, Reinoso Webb C, Furr KL, Grisham MB. Role of the enteric microbiota in intestinal homeostasis and inflammation. *Free Radic Biol Med* [Internet]. 2014 Mar [cited 2018 Oct 10];68:122–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24275541>
87. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, et al. Gut Immune Maturation Depends on Colonization with a Host-Specific Microbiota. *Cell* [Internet]. 2012 Jun 22 [cited 2018 Oct 10];149(7):1578–93. Available from:

- <http://www.ncbi.nlm.nih.gov/pubmed/22726443>
88. Ivanov II, Littman DR. Modulation of immune homeostasis by commensal bacteria. *Curr Opin Microbiol* [Internet]. 2011 Feb [cited 2018 Oct 10];14(1):106–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21215684>
 89. Alam M, Midtvedt T, Uribe A. Differential cell kinetics in the ileum and colon of germfree rats. *Scand J Gastroenterol* [Internet]. 1994 May [cited 2018 Oct 10];29(5):445–51. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8036460>
 90. Gustafsson BE, Midtvedt T, Strandberg K. Effects of microbial contamination on the cecum enlargement of germfree rats. *Scand J Gastroenterol* [Internet]. 1970 [cited 2018 Oct 10];5(4):309–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/5429896>
 91. Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. *FEBS Lett*. Federation of European Biochemical Societies; 2014 Oct;588(22):4223–33.
 92. Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalahti J, et al. Molecular analysis of the gut microbiota of identical twins with Crohn’s disease. *ISME J* [Internet]. 2008 Jul 10 [cited 2018 Apr 20];2(7):716–27. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18401439>
 93. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* [Internet]. National Academy of Sciences; 2007 Aug 21 [cited 2018 Apr 20];104(34):13780–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17699621>
 94. Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. *Adv Ther* [Internet]. 2018 Mar 1 [cited 2018 Apr 20];35(3):289–310. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29498019>
 95. Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular Characterisation of the Faecal Microbiota in Patients with Type II Diabetes. *Curr Microbiol* [Internet]. 2010 Jul 20 [cited 2018 Apr 20];61(1):69–78. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20087741>

96. Arrieta M-C, Arévalo A, Stiemsma L, Dimitriu P, Chico ME, Loor S, et al. Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting. *J Allergy Clin Immunol* [Internet]. 2017 Dec 30 [cited 2018 Apr 20]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29241587>
97. Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T, et al. Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer. *Dig Dis Sci*. 2013;58(6):1717–26.
98. Lupton JR. Microbial Degradation Products Influence Colon Cancer Risk: the Butyrate Controversy. *J Nutr* [Internet]. 2004 Feb 1 [cited 2018 Apr 20];134(2):479–82. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/14747692>
99. Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. In: *Advances in experimental medicine and biology* [Internet]. 2018 [cited 2018 Jul 10]. p. 111–25. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29956210>
100. Jia W, Rajani C. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. In: *Advances in experimental medicine and biology* [Internet]. 2018 [cited 2018 Jul 10]. p. 95–110. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29956209>
101. Gonzalez A, Stombaugh J, Lozupone C, Turnbaugh PJ, Gordon JI, Knight R. The mind-body-microbial continuum. *Dialogues Clin Neurosci* [Internet]. 2011 [cited 2018 Apr 20];13(1):55–62. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21485746>
102. Pulikkan J, Maji A, Dhakan DB, Saxena R, Mohan B, Anto MM, et al. Gut Microbial Dysbiosis in Indian Children with Autism Spectrum Disorders. *Microb Ecol* [Internet]. 2018 Mar 21 [cited 2018 Apr 20]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29564487>
103. Andoh A, Kuzuoka H, Tsujikawa T, Nakamura S, Hirai F, Suzuki Y, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. *J Gastroenterol*. 2012;47(12):1298–307.
104. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. *Gut*. 2004;53(5):685–93.

105. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut*. 2011;60(5):631–7.
106. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis*. 2009;15(8):1183–9.
107. Sokol H, Lepage P, Seksik P, Doré J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active *Escherichia coli* in the microbiota of patients with ulcerative colitis. *J Clin Microbiol*. 2006;44(9):3172–7.
108. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. *Gastroenterology*. 2004;127(2):412–21.
109. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of *Clostridium difficile* infection in inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2007;5(3):339–44.
110. Huda-Faujan N, Abdulamir AS, Fatimah AB, Anas OM, Shuhaimi M, Yazid AM, et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. *Open Biochem J*. 2010;4(1c):53–8.
111. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J Exp Med* [Internet]. 1994 Dec 1 [cited 2018 Jan 6];180(6):2359–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7964509>
112. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. *Am J Pathol* [Internet]. American Society for Investigative Pathology; 1997 Jan [cited 2018 Jan 6];150(1):91–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9006326>
113. Hudcovic T, Stěpánková R, Cebra J, Tlaskalová-Hogenová H. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. *Folia Microbiol (Praha)* [Internet]. 2001 [cited 2018 Jan 6];46(6):565–72. Available

- from: <http://www.ncbi.nlm.nih.gov/pubmed/11898350>
114. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJO. Differences between Tissue-Associated Intestinal Microfloras of Patients with Crohn's Disease and Ulcerative Colitis. *J Clin Microbiol* [Internet]. 2006 Nov 1 [cited 2018 Jan 6];44(11):4136–41. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16988016>
 115. Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci* [Internet]. 2007 Aug 21 [cited 2018 Jan 6];104(34):13780–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17699621>
 116. Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. *J Biomed Biotechnol* [Internet]. 2012 [cited 2018 May 7];2012:718617. Available from: <http://www.hindawi.com/journals/bmri/2012/718617/>
 117. Martín R, Chain F, Miquel S, Motta J-P, Vergnolle N, Sokol H, et al. Using murine colitis models to analyze probiotics–host interactions. *FEMS Microbiol Rev* [Internet]. 2017 Aug 1 [cited 2018 Apr 21];41(Supp_1):S49–70. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28830096>
 118. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. *Nat Protoc* [Internet]. Nature Publishing Group; 2007 Mar 1 [cited 2018 Oct 2];2(3):541–6. Available from: <http://www.nature.com/articles/nprot.2007.41>
 119. Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. *World J Gastroenterol* [Internet]. 2007 Nov 14 [cited 2018 Oct 2];13(42):5581–93. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17948932>
 120. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. *Gastroenterology* [Internet]. W.B. Saunders; 1994 Dec 1 [cited 2018 Oct 2];107(6):1643–52. Available from: <https://www.sciencedirect.com/science/article/pii/0016508594908036>
 121. Yoda K, Miyazawa K, Hosoda M, Hiramatsu M, Yan F, He F. Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial

- homeostasis through activation of epidermal growth factor receptor. *Eur J Nutr* [Internet]. NIH Public Access; 2014 Feb [cited 2018 Oct 16];53(1):105–15. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23468308>
122. Sham HP, Yu EYS, Gulen MF, Bhinder G, Stahl M, Chan JM, et al. SIGIRR, a Negative Regulator of TLR/IL-1R Signalling Promotes Microbiota Dependent Resistance to Colonization by Enteric Bacterial Pathogens. Philpott DJ, editor. *PLoS Pathog* [Internet]. Public Library of Science; 2013 Aug 8 [cited 2018 Oct 2];9(8):e1003539. Available from: <http://dx.plos.org/10.1371/journal.ppat.1003539>
 123. Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. *Gut Microbes* [Internet]. 2012 Nov 16 [cited 2018 Oct 2];3(6):544–55. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23060017>
 124. ECKMANN L. Animal Models of Inflammatory Bowel Disease: Lessons from Enteric Infections. *Ann N Y Acad Sci* [Internet]. 2006 Aug 1 [cited 2018 Oct 2];1072(1):28–38. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17057188>
 125. Mundy R, MacDonald TT, Dougan G, Frankel G, Wiles S. *Citrobacter rodentium* of mice and man. *Cell Microbiol* [Internet]. 2005 Dec [cited 2018 Oct 2];7(12):1697–706. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16309456>
 126. Bhinder G, Sham HP, Chan JM, Morampudi V, Jacobson K, Vallance BA. The *Citrobacter rodentium* mouse model: studying pathogen and host contributions to infectious colitis. *J Vis Exp* [Internet]. MyJoVE Corporation; 2013 Feb 19 [cited 2018 Aug 13];(72):e50222. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23462619>
 127. Petty NK, Bulgin R, Crepin VF, Cerdeno-Tarraga AM, Schroeder GN, Quail MA, et al. The *Citrobacter rodentium* Genome Sequence Reveals Convergent Evolution with Human Pathogenic *Escherichia coli*. *J Bacteriol* [Internet]. 2010 Jan 15 [cited 2018 Oct 2];192(2):525–38. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19897651>
 128. Vallance BA, Deng W, Jacobson K, Finlay BB. Host susceptibility to the attaching and effacing bacterial pathogen *Citrobacter rodentium*. *Infect Immun* [Internet]. 2003 Jun [cited 2018 Oct 2];71(6):3443–53. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12761129>
 129. Bosman ES, Chan JM, Bhullar K, Vallance BA. Investigation of Host and Pathogen

- Contributions to Infectious Colitis Using the *Citrobacter rodentium* Mouse Model of Infection. In: Methods in molecular biology (Clifton, NJ) [Internet]. 2016 [cited 2018 Oct 2]. p. 225–41. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27246037>
130. Bergstrom KSB, Kisooson-Singh V, Gibson DL, Ma C, Montero M, Sham HP, et al. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog [Internet]. Public Library of Science; 2010 May 13 [cited 2018 Aug 13];6(5):e1000902. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20485566>
 131. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol [Internet]. 2008 May 5 [cited 2018 Oct 2];1(3):183–97. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19079178>
 132. Dharmani P, Srivastava V, Kisooson-Singh V, Chadee K. Role of Intestinal Mucins in Innate Host Defense Mechanisms against Pathogens. J Innate Immun [Internet]. 2009 [cited 2018 Oct 2];1(2):123–35. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20375571>
 133. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Genes and Molecules of Lactobacilli Supporting Probiotic Action. Microbiol Mol Biol Rev [Internet]. 2008 Dec 1 [cited 2018 Jan 6];72(4):728–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19052326>
 134. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol [Internet]. 2009 Jan 22 [cited 2018 Jan 6];44(1):26–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19159071>
 135. Wells JM. Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact [Internet]. 2011 Aug 30 [cited 2018 Jan 7];10(Suppl 1):S17. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21995674>
 136. Mann ER, You J, Horneffer-van der Sluis V, Bernardo D, Omar Al-Hassi H, Landy J, et al. Dysregulated Circulating Dendritic Cell Function in Ulcerative Colitis Is Partially Restored by Probiotic Strain *Lactobacillus casei* Shirota. Mediators Inflamm [Internet]. 2013 [cited 2018 Jan 7];2013:1–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23970814>
 137. Mann ER, Bernardo D, Ng SC, Rigby RJ, Al-Hassi HO, Landy J, et al. Human Gut

- Dendritic Cells Drive Aberrant Gut-specific T-cell Responses in Ulcerative Colitis, Characterized by Increased IL-4 Production and Loss of IL-22 and IFN γ . *Inflamm Bowel Dis* [Internet]. 2014 Dec [cited 2018 Jan 7];20(12):2299–307. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25397892>
138. Wu Y, Zhu C, Chen Z, Chen Z, Zhang W, Ma X, et al. Protective effects of *Lactobacillus plantarum* on epithelial barrier disruption caused by enterotoxigenic *Escherichia coli* in intestinal porcine epithelial cells. *Vet Immunol Immunopathol* [Internet]. 2016 Apr [cited 2018 Jan 7];172:55–63. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27032504>
 139. Roselli M, Finamore A, Nuccitelli S, Carnevali P, Brigidi P, Vitali B, et al. Prevention of TNBS-induced colitis by different *Lactobacillus* and *Bifidobacterium* strains is associated with an expansion of $\gamma\delta$ T and regulatory T cells of intestinal intraepithelial lymphocytes. *Inflamm Bowel Dis* [Internet]. 2009 Oct [cited 2018 Jan 7];15(10):1526–36. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19504616>
 140. Hacini-Rachinel F, Nancey S, Boschetti G, Sardi F, Doucet-Ladeveze R, Durand P-Y, et al. CD4⁺ T Cells and *Lactobacillus casei* Control Relapsing Colitis Mediated by CD8⁺ T Cells. *J Immunol* [Internet]. 2009 Nov 1 [cited 2018 Jan 7];183(9):5477–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19843933>
 141. Dai C, Zheng C-Q, Meng F, Zhou Z, Sang L, Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF- κ B pathway in rat model of DSS-induced colitis. *Mol Cell Biochem* [Internet]. 2013 Feb 23 [cited 2018 Jan 7];374(1–2):1–11. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23271629>
 142. Salim SY, Young PY, Lukowski CM, Madsen KL, Sis B, Churchill TA, et al. VSL#3 probiotics provide protection against acute intestinal ischaemia/reperfusion injury. *Benef Microbes* [Internet]. 2013 Dec 1 [cited 2018 Jan 7];4(4):357–65. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24240573>
 143. Talero E, Bolivar S, Ávila-Román J, Alcaide A, Fiorucci S, Motilva V. Inhibition of Chronic Ulcerative Colitis-associated Adenocarcinoma Development in Mice by VSL#3. *Inflamm Bowel Dis* [Internet]. 2015 May [cited 2018 Jan 7];21(5):1027–37. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25793324>
 144. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, et al.

- Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. *Inflamm Bowel Dis* [Internet]. 2002 Mar [cited 2018 Jan 7];8(2):71–80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11854603>
145. DuPont A, Richards DM, Jelinek KA, Krill J, Rahimi E, Ghouri Y. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. *Clin Exp Gastroenterol* [Internet]. 2014 Dec [cited 2018 Jan 7];7:473. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25525379>
 146. Whelan K, Quigley EMM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. *Curr Opin Gastroenterol* [Internet]. 2013 Mar [cited 2018 Jan 7];29(2):184–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23286925>
 147. Veerappan GR, Betteridge J, Young PE. Probiotics for the Treatment of Inflammatory Bowel Disease. *Curr Gastroenterol Rep* [Internet]. 2012 Aug 13 [cited 2018 Jan 7];14(4):324–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22581276>
 148. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by *Lactococcus lactis* secreting interleukin-10. *Science* [Internet]. 2000 Aug 25 [cited 2018 Jan 7];289(5483):1352–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10958782>
 149. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon J, et al. A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease. *Clin Gastroenterol Hepatol* [Internet]. 2006 Jun [cited 2018 Jan 7];4(6):754–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16716759>
 150. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, et al. Active delivery of trefoil factors by genetically modified *Lactococcus lactis* prevents and heals acute colitis in mice. *Gastroenterology* [Internet]. 2004 Aug [cited 2018 Jan 7];127(2):502–13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15300583>
 151. Maldonado-Gómez MX, Martínez I, Bottacini F, O’Callaghan A, Ventura M, van Sinderen D, et al. Stable Engraftment of *Bifidobacterium longum* AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome. *Cell Host Microbe* [Internet]. 2016 Oct 12 [cited 2018 Jan 7];20(4):515–26. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27693307>

152. Zmora N, Zeevi D, Korem T, Segal E, Elinav E. Taking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease. *Cell Host Microbe* [Internet]. Elsevier; 2016 Jan 13 [cited 2018 Jan 10];19(1):12–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26764593>
153. Jameson JL, Longo DL. Precision Medicine — Personalized, Problematic, and Promising. *N Engl J Med* [Internet]. 2015 Jun 4 [cited 2018 Apr 21];372(23):2229–34. Available from: <http://www.nejm.org/doi/10.1056/NEJMs1503104>
154. Rebbeck TR, Friebe T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* [Internet]. American Society of Clinical Oncology; 2004 Mar 15 [cited 2018 May 1];22(6):1055–62. Available from: <http://ascopubs.org/doi/10.1200/JCO.2004.04.188>
155. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. *Nature* [Internet]. Nature Publishing Group; 2009 Jan 22 [cited 2018 May 1];457(7228):480–4. Available from: <http://www.nature.com/doi/10.1038/nature07540>
156. Arrieta M-C, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med* [Internet]. American Association for the Advancement of Science; 2015 Sep 30 [cited 2018 May 1];7(307):307ra152. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26424567>
157. Taneja V. Arthritis susceptibility and the gut microbiome. *FEBS Lett* [Internet]. Wiley-Blackwell; 2014 Nov 17 [cited 2018 May 1];588(22):4244–9. Available from: <http://doi.wiley.com/10.1016/j.febslet.2014.05.034>
158. Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. *Tissue barriers* [Internet]. Taylor & Francis; 2015 [cited 2018 Oct 6];3(1–2):e982426. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25838985>
159. Johansson ME V, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. *Nat Rev Gastroenterol Hepatol* [Internet]. NIH Public Access; 2013 Jun [cited 2018 Oct 7];10(6):352–61. Available from:

- <http://www.ncbi.nlm.nih.gov/pubmed/23478383>
160. Johansson ME V., Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. *Proc Natl Acad Sci* [Internet]. 2008 Sep 30 [cited 2018 Oct 7];105(39):15064–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18806221>
 161. van Klinken BJ, Einerhand AW, Duits LA, Makkink MK, Tytgat KM, Renes IB, et al. Gastrointestinal expression and partial cDNA cloning of murine Muc2. *Am J Physiol* [Internet]. 1999 Jan [cited 2018 Oct 16];276(1 Pt 1):G115-24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9886986>
 162. Tytgat KM, Büller HA, Opdam FJ, Kim YS, Einerhand AW, Dekker J. Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. *Gastroenterology* [Internet]. 1994 Nov [cited 2018 Oct 16];107(5):1352–63. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7926500>
 163. Hattrup CL, Gendler SJ. Structure and Function of the Cell Surface (Tethered) Mucins. *Annu Rev Physiol* [Internet]. 2008 Mar [cited 2018 Oct 16];70(1):431–57. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17850209>
 164. Jonckheere N, Skrypek N, Van Seuningen I. Mucins and pancreatic cancer. *Cancers (Basel)* [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2010 Oct 25 [cited 2018 Oct 21];2(4):1794–812. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24281201>
 165. Perez-Vilar J, Hill RL. The structure and assembly of secreted mucins. *J Biol Chem* [Internet]. 1999 Nov 5 [cited 2018 Oct 16];274(45):31751–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10542193>
 166. McGuckin MA, Lindén SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. *Nat Rev Microbiol* [Internet]. 2011 Apr 1 [cited 2018 Oct 16];9(4):265–78. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21407243>
 167. Johansson ME V., Larsson JMH, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci* [Internet]. 2011 Mar 15 [cited 2018 Oct 16];108(Supplement_1):4659–65. Available from:

- <http://www.ncbi.nlm.nih.gov/pubmed/20615996>
168. Specian RD, Oliver MG. Functional biology of intestinal goblet cells. *Am J Physiol Physiol* [Internet]. 1991 Feb [cited 2018 Oct 16];260(2):C183–93. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1996606>
 169. Arike L, Hansson GC. The Densely O-Glycosylated MUC2 Mucin Protects the Intestine and Provides Food for the Commensal Bacteria. *J Mol Biol* [Internet]. NIH Public Access; 2016 [cited 2018 May 3];428(16):3221–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26880333>
 170. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. *Glycobiology* [Internet]. 2012 Jun 1 [cited 2018 Oct 16];22(6):736–56. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22183981>
 171. Bergstrom KSB, Xia L. Mucin-type O-glycans and their roles in intestinal homeostasis. *Glycobiology* [Internet]. Oxford University Press; 2013 Sep [cited 2018 Aug 13];23(9):1026–37. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23752712>
 172. Thomsson KA, Holmén-Larsson JM, Ångström J, Johansson ME, Xia L, Hansson GC. Detailed O-glycomics of the Muc2 mucin from colon of wild-type, core 1- and core 3-transferase-deficient mice highlights differences compared with human MUC2. *Glycobiology* [Internet]. 2012 Aug [cited 2018 Oct 16];22(8):1128–39. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22581805>
 173. Holmén Larsson JM, Karlsson H, Sjövall H, Hansson GC. A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. *Glycobiology* [Internet]. 2009 Jul [cited 2018 Oct 16];19(7):756–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19321523>
 174. Rokhsafat S, Lin A, Comelli EM. Mucin–Microbiota Interaction During Postnatal Maturation of the Intestinal Ecosystem: Clinical Implications. *Dig Dis Sci* [Internet]. Springer US; 2016 Jun 20 [cited 2018 Oct 20];61(6):1473–86. Available from: <http://link.springer.com/10.1007/s10620-016-4032-6>
 175. Johansson MEV, Jakobsson HE, Holmén-Larsson J, Schütte A, Ermund A, Rodríguez-Piñeiro AM, et al. Normalization of Host Intestinal Mucus Layers Requires Long-Term

- Microbial Colonization. *Cell Host Microbe* [Internet]. Elsevier; 2015 Nov 11 [cited 2018 Oct 20];18(5):582–92. Available from:
<https://linkinghub.elsevier.com/retrieve/pii/S1931312815004175>
176. Arike L, Holmén-Larsson J, Hansson GC. Intestinal Muc2 mucin O-glycosylation is affected by microbiota and regulated by differential expression of glycosyltransferases. *Glycobiology* [Internet]. Oxford University Press; 2017 Apr 1 [cited 2018 May 3];27(4):318–28. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28122822>
 177. Morampudi V, Dalwadi U, Bhinder G, Sham HP, Gill SK, Chan J, et al. The goblet cell-derived mediator RELM- β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. *Mucosal Immunol* [Internet]. 2016 Sep 27 [cited 2018 Jul 25];9(5):1218–33. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/26813339>
 178. Tailford LE, Crost EH, Kavanaugh D, Juge N. Mucin glycan foraging in the human gut microbiome. *Front Genet* [Internet]. 2015 Mar 19 [cited 2018 Oct 20];6:81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25852737>
 179. Martens EC, Chiang HC, Gordon JI. Mucosal glycan foraging enhances fitness and transmission of a saccharolytic human gut bacterial symbiont. *Cell Host Microbe* [Internet]. NIH Public Access; 2008 Nov 13 [cited 2018 Oct 21];4(5):447–57. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18996345>
 180. Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, et al. A Genomic View of the Human-Bacteroides thetaiotaomicron Symbiosis. *Science* (80-) [Internet]. 2003 Mar 28 [cited 2018 Oct 21];299(5615):2074–6. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/12663928>
 181. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and *Akkermansia muciniphila*, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. *Appl Environ Microbiol* [Internet]. American Society for Microbiology (ASM); 2007 Dec [cited 2018 Oct 21];73(23):7767–70. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/17933936>
 182. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The Mucin degrader *Akkermansia muciniphila* is an abundant resident of the human intestinal tract. *Appl*

- Environ Microbiol [Internet]. American Society for Microbiology (ASM); 2008 Mar [cited 2018 Oct 21];74(5):1646–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18083887>
183. Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog [Internet]. 2017 May [cited 2018 Jan 10];106:171–81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26875998>
 184. Fujita K, Oura F, Nagamine N, Katayama T, Hiratake J, Sakata K, et al. Identification and Molecular Cloning of a Novel Glycoside Hydrolase Family of Core 1 Type O -Glycan-specific Endo- α -N-acetylgalactosaminidase from *Bifidobacterium longum*. J Biol Chem [Internet]. 2005 Nov 11 [cited 2018 Oct 22];280(45):37415–22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16141207>
 185. Turrone F, Bottacini F, Foroni E, Mulder I, Kim J-H, Zomer A, et al. Genome analysis of *Bifidobacterium bifidum* PRL2010 reveals metabolic pathways for host-derived glycan foraging. Proc Natl Acad Sci [Internet]. 2010 Nov 9 [cited 2018 Oct 22];107(45):19514–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20974960>
 186. Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol [Internet]. Springer Japan; 2017 Jan 23 [cited 2018 Oct 22];52(1):1–8. Available from: <http://link.springer.com/10.1007/s00535-016-1242-9>
 187. Rivera-Chávez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, et al. Depletion of Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of Salmonella. Cell Host Microbe [Internet]. Elsevier; 2016 Apr 13 [cited 2018 Jan 15];19(4):443–54. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S1931312816300968>
 188. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe [Internet]. Cell Press; 2015 May 13 [cited 2018 Oct 22];17(5):662–71. Available from: <https://www.sciencedirect.com/science/article/pii/S1931312815001225>
 189. Levy M, Kolodziejczyk AA, Thaïs CA, Elinav E. Dysbiosis and the immune system. Nat

- Rev Immunol [Internet]. 2017 Apr 6 [cited 2018 Jul 10];17(4):219–32. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28260787>
190. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol [Internet]. Wiley-Blackwell; 2014 Jul [cited 2018 Jul 10];16(7):1024–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24798552>
 191. Hooks KB, O'Malley MA. Dysbiosis and Its Discontents. MBio [Internet]. American Society for Microbiology (ASM); 2017 [cited 2018 Jul 10];8(5). Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29018121>
 192. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe [Internet]. NIH Public Access; 2015 May 13 [cited 2018 Jul 10];17(5):553–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25974298>
 193. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol [Internet]. 2009 Jan 22 [cited 2018 Apr 21];44(1):26–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19159071>
 194. Khalesi S, Bellissimo • Nick, Vandelandotte • Corneel, Williams S, Stanley D, Irwin C. A review of probiotic supplementation in healthy adults: helpful or hype? Eur J Clin Nutr [Internet]. [cited 2018 Apr 11]; Available from: <https://doi.org/10.1038/s41430-018-0135-9>
 195. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(3):286–99.
 196. Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol [Internet]. 2007 Nov [cited 2018 Aug 12];23(6):679–92. Available from: <https://insights.ovid.com/crossref?an=00001574-200711000-00016>
 197. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol [Internet]. Elsevier Current Trends; 2006 Apr 1 [cited 2018 Aug 12];17(2):204–10. Available from: https://www.sciencedirect.com/science/article/pii/S0958166906000309?_rdoc=1&_fmt=high&_origin=gateway&_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb
 198. Celiberto LS, Bedani R, Rossi EA, Cavallini DCU. Probiotics: The Scientific Evidence in the Context of Inflammatory Bowel Disease. Crit Rev Food Sci Nutr [Internet]. 2015;0.

- Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25996176>
199. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* [Internet]. 2014 Aug 10 [cited 2018 Apr 20];11(8):506–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24912386>
 200. Reid G. Probiotics: definition, scope and mechanisms of action. *Best Pract Res Clin Gastroenterol* [Internet]. Baillière Tindall; 2016 Feb 1 [cited 2018 Jul 11];30(1):17–25. Available from: <https://www.sciencedirect.com/science/article/pii/S1521691815001651>
 201. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. *Nutrition* [Internet]. Elsevier; 2018 Jan 1 [cited 2018 Jul 11];45:125–134.e11. Available from: <https://www.sciencedirect.com/science/article/pii/S0899900717301351>
 202. Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the intestinal microbiota influences health and disease. *Nat Rev Microbiol* [Internet]. 2017 Jun 19 [cited 2018 Apr 20];15(10):630–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28626231>
 203. McNaughton SJ. Diversity and Stability of Ecological Communities: A Comment on the Role of Empiricism in Ecology [Internet]. Vol. 111, *The American Naturalist*. The University of Chicago Press; The American Society of Naturalists; [cited 2018 Apr 21]. p. 515–25. Available from: <https://www.jstor.org/stable/2460237>
 204. Naeem S, Li S. Biodiversity enhances ecosystem reliability. *Nature* [Internet]. Nature Publishing Group; 1997 Dec 4 [cited 2018 Apr 21];390(6659):507–9. Available from: <http://www.nature.com/articles/37348>
 205. Kort R. Personalized therapy with probiotics from the host by TripleA. *Trends Biotechnol* [Internet]. Elsevier Ltd; 2014;32(6):291–3. Available from: <http://dx.doi.org/10.1016/j.tibtech.2014.04.002>
 206. Pelczar MJ. *Microbiology* [Internet]. Tata McGraw-Hill; 2003 [cited 2018 Apr 20]. 918 p. Available from: <https://books.google.ca/books/about/Microbiology.html?id=BKq5iXPHMlcC>

207. Heilig HGJ, Zoetendal EG, Vaughan EE, Marteau P, Akkermans ADL, de Vos WM. Molecular Diversity of *Lactobacillus* spp . and Other Lactic Acid Bacteria in the Human Intestine as Determined by Specific Amplification of 16S Ribosomal DNA Molecular Diversity of *Lactobacillus* spp . and Other Lactic Acid Bacteria in the Human Intestine. *Appl Environ Microbiol*. 2002;68(1):114–23.
208. Vincent D, Roy D, Mondou F, Déry C. Characterization of bifidobacteria by random DNA amplification. *Int J Food Microbiol* [Internet]. Elsevier; 1998 Sep 8 [cited 2018 Apr 20];43(3):185–93. Available from: <https://www.sciencedirect.com/science/article/pii/S0168160598001093?via%3Dihub>
209. Liserre AM, Ré MI, Franco BDGM. Microencapsulation of *Bifidobacterium animalis* subsp. *lactis* in Modified Alginate-chitosan Beads and Evaluation of Survival in Simulated Gastrointestinal Conditions. *Food Biotechnol* [Internet]. Taylor & Francis Group ; 2007 Mar 6 [cited 2018 Apr 20];21(1):1–16. Available from: <http://www.tandfonline.com/doi/abs/10.1080/08905430701191064>
210. Buriti FCA, Castro IA, Saad SMI. Viability of *Lactobacillus acidophilus* in synbiotic guava mousses and its survival under in vitro simulated gastrointestinal conditions. *Int J Food Microbiol* [Internet]. 2010 Feb 28 [cited 2018 Apr 20];137(2–3):121–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20056289>
211. Clinical and Laboratory Standards Institute. [cited 2018 Apr 20]; Available from: <http://demo.nextlab.ir/getattachment/27407437-3d73-4048-8239-81857d68cf3d/CLSI-M2-A9.aspx>
212. Performance Standards for Antimicrobial Susceptibility Testing An informational supplement for global application developed through the Clinical and Laboratory Standards Institute. [cited 2018 Apr 20]; Available from: <http://ljzx.cqrmhospital.com/upfiles/201601/20160112155335884.pdf>
213. Segers ME, Lebeer S. Towards a better understanding of *Lactobacillus rhamnosus* GG - host interactions. *Microb Cell Fact* [Internet]. 2014 Aug 29 [cited 2018 May 1];13(Suppl 1):S7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25186587>
214. Szajewska H, Kołodziej M. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults.

- Aliment Pharmacol Ther [Internet]. 2015 Nov [cited 2018 May 1];42(10):1149–57. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26365389>
215. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest [Internet]. 1993 Aug [cited 2018 Jul 2];69(2):238–49. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8350599>
 216. Ryz NR, Lochner A, Bhullar K, Ma C, Huang T, Bhinder G, et al. Dietary vitamin D3 deficiency alters intestinal mucosal defense and increases susceptibility to *Citrobacter rodentium*-induced colitis. Am J Physiol Gastrointest Liver Physiol [Internet]. American Physiological Society; 2015 Nov 1 [cited 2018 Jul 2];309(9):G730–42. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26336925>
 217. Zarepour M, Bhullar K, Montero M, Ma C, Huang T, Velcich A, et al. The mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during *Salmonella enterica* serovar Typhimurium colitis. Infect Immun [Internet]. American Society for Microbiology (ASM); 2013 Oct [cited 2018 Jul 2];81(10):3672–83. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23876803>
 218. Eissa N, Hussein H, Wang H, Rabbi MF, Bernstein CN, Ghia J-E. Stability of Reference Genes for Messenger RNA Quantification by Real-Time PCR in Mouse Dextran Sodium Sulfate Experimental Colitis. PLoS One [Internet]. Public Library of Science; 2016 [cited 2018 Jul 2];11(5):e0156289. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27244258>
 219. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc [Internet]. 2008 [cited 2018 Jul 2];3(6):1101–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18546601>
 220. Goldstein EJC, Tyrrell KL, Citron DM. Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities. Clin Infect Dis [Internet]. Oxford University Press; 2015 May 15 [cited 2018 May 6];60(suppl_2):S98–107. Available from: http://academic.oup.com/cid/article/60/suppl_2/S98/379146/Lactobacillus-Species-Taxonomic-Complexity-and
 221. Muñoa FJ, Pares R. Selective medium for isolation and enumeration of *Bifidobacterium* spp. Appl Environ Microbiol [Internet]. American Society for Microbiology (ASM); 1988

- Jul [cited 2018 May 6];54(7):1715–8. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/3415235>
222. Xiao L, Feng Q, Liang S, Sonne SB, Xia Z, Qiu X, et al. A catalog of the mouse gut metagenome. *Nat Biotechnol* [Internet]. 2015 Oct 28 [cited 2018 May 6];33(10):1103–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26414350>
 223. Chen S, Chen L, Chen L, Ren X, Ge H, Li B, et al. Potential probiotic characterization of *Lactobacillus reuteri* from traditional Chinese highland barley wine and application for room-temperature-storage drinkable yogurt. *J Dairy Sci* [Internet]. 2018 Apr 25 [cited 2018 May 7]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29705426>
 224. Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. *Cell* [Internet]. Elsevier; 2018 Sep 6 [cited 2018 Sep 8];174(6):1388–1405.e21. Available from:
<https://linkinghub.elsevier.com/retrieve/pii/S0092867418311024>
 225. De Vuyst L, Neysens P. The sourdough microflora: biodiversity and metabolic interactions. *Trends Food Sci Technol* [Internet]. Elsevier; 2005 Jan 1 [cited 2018 Jul 2];16(1–3):43–56. Available from:
<https://www.sciencedirect.com/science/article/abs/pii/S092422440400192X>
 226. Ehrmann MA, Müller MRA, Vogel RF. Molecular analysis of sourdough reveals *Lactobacillus mindensis* sp. nov. *Int J Syst Evol Microbiol* [Internet]. 2003 Jan 1 [cited 2018 Jul 2];53(1):7–13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12656145>
 227. Hayford AE, Petersen A, Vogensen FK, Jakobsen M. Use of conserved randomly amplified polymorphic DNA (RAPD) fragments and RAPD pattern for characterization of *Lactobacillus fermentum* in Ghanaian fermented maize dough. *Appl Environ Microbiol* [Internet]. 1999 Jul [cited 2018 Jul 2];65(7):3213–21. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/10388723>
 228. Venturi M, Guerrini S, Granchi L, Vincenzini M. Typing of *Lactobacillus sanfranciscensis* isolates from traditional sourdoughs by combining conventional and multiplex RAPD–PCR profiles. *Int J Food Microbiol* [Internet]. Elsevier; 2012 May 15 [cited 2018 Apr 23];156(2):122–6. Available from:

- <https://www.sciencedirect.com/science/article/pii/S0168160512001304#bb0050>
229. Gueimonde M, Sánchez B, G. de los Reyes-Gavilán C, Margolles A. Antibiotic resistance in probiotic bacteria. *Front Microbiol* [Internet]. 2013 [cited 2018 Jul 2];4:202. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23882264>
 230. Zhou JS, Pillidge CJ, Gopal PK, Gill HS. Antibiotic susceptibility profiles of new probiotic *Lactobacillus* and *Bifidobacterium* strains. *Int J Food Microbiol* [Internet]. 2005 Feb 1 [cited 2018 Jul 3];98(2):211–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15681048>
 231. Mayrhofer S, Mair C, Kneifel W, Domig KJ. Susceptibility of *Bifidobacteria* of Animal Origin to Selected Antimicrobial Agents. *Chemother Res Pract* [Internet]. 2011 [cited 2018 Jul 3];2011:1–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22312561>
 232. Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. *J Biomed Biotechnol* [Internet]. Hindawi Limited; 2012 [cited 2018 Jul 23];2012:718617. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22665990>
 233. Eichele DD, Kharbanda KK. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. *World J Gastroenterol* [Internet]. Baishideng Publishing Group Inc; 2017 Sep 7 [cited 2018 Jul 23];23(33):6016–29. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28970718>
 234. König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, Mercenier A, et al. Human Intestinal Barrier Function in Health and Disease. *Clin Transl Gastroenterol* [Internet]. Nature Publishing Group; 2016 Oct 20 [cited 2018 Jul 23];7(10):e196–e196. Available from: <http://www.nature.com/articles/ctg201654>
 235. Michielan A, D’Inca R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. *Mediators Inflamm* [Internet]. Hindawi Limited; 2015 [cited 2018 Jul 23];2015:628157. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26582965>
 236. Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. *Gastroenterology* [Internet]. 2017 Sep [cited 2018

- Jul 23];153(3):723–731.e1. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/28601482>
237. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? *Inflamm Intest Dis* [Internet]. Karger Publishers; 2016 [cited 2018 Jul 23];1(3):135–45. Available from:
<https://www.karger.com/Article/FullText/447252>
 238. Mijan M Al, Lim BO. Diets, functional foods, and nutraceuticals as alternative therapies for inflammatory bowel disease: Present status and future trends. *World J Gastroenterol* [Internet]. Baishideng Publishing Group Inc; 2018 Jul 7 [cited 2018 Jul 23];24(25):2673–85. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29991873>
 239. Celiberto LS, Bedani R, Dejana NN, Ivo de Medeiros A, Sampaio Zuanon JA, Spolidorio LC, et al. Effect of a probiotic beverage consumption (*Enterococcus faecium* CRL 183 and *Bifidobacterium longum* ATCC 15707) in rats with chemically induced colitis. Smidt H, editor. *PLoS One* [Internet]. Public Library of Science; 2017 Apr 24 [cited 2018 May 4];12(4):e0175935. Available from: <http://dx.plos.org/10.1371/journal.pone.0175935>
 240. Seo S, Shin JS, Lee WS, Rhee YK, Cho CW, Hong H Do, et al. Anti-colitis effect of *Lactobacillus sakei* K040706 via suppression of inflammatory responses in the dextran sulfate sodium-induced colitis mice model. *J Funct Foods* [Internet]. Elsevier Ltd; 2017;29(December):256–68. Available from: <http://dx.doi.org/10.1016/j.jff.2016.12.045>
 241. Shigemori S, Watanabe T, Kudoh K, Ihara M, Nigar S, Yamamoto Y, et al. Oral delivery of *Lactococcus lactis* that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. *Microb Cell Fact* [Internet]. 2015 Dec 25 [cited 2018 Jul 23];14(1):189. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26608030>
 242. Park J-S, Joe I, Rhee PD, Jeong C-S, Jeong G. A lactic acid bacterium isolated from kimchi ameliorates intestinal inflammation in DSS-induced colitis. *J Microbiol* [Internet]. 2017 Apr 26 [cited 2018 Jul 23];55(4):304–10. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/28124779>
 243. Camuesco D, Peran L, Comalada M, Nieto A, Di Stasi LC, Rodriguez-Cabezas ME, et al. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. *Inflamm Bowel Dis* [Internet]. 2005 Mar [cited 2018 May 29];11(3):265–71. Available

- from: <http://www.ncbi.nlm.nih.gov/pubmed/15735433>
244. Osman N, Adawi D, Molin G, Ahrne S, Berggren A, Jeppsson B. Bifidobacterium infantis strains with and without a combination of oligofructose and inulin attenuate inflammation in DSS-induced colitis in rats. *BMC Gastroenterol*. 2006;6:31.
 245. Krieglstein CF, Anthoni C, Cerwinka WH, Stokes KY, Russell J, Grisham MB, et al. Role of Blood- and Tissue-Associated Inducible Nitric-Oxide Synthase in Colonic Inflammation. *Am J Pathol* [Internet]. 2007 Feb [cited 2018 Jul 21];170(2):490–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17255317>
 246. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen T-E, Conklin LS, et al. Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced Colitis. *Inflamm Bowel Dis* [Internet]. 2009 Mar [cited 2018 Jul 21];15(3):341–52. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18942757>
 247. Ramasamy S, Nguyen DD, Eston MA, Alam SN, Moss AK, Ebrahimi F, et al. Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. *Inflamm Bowel Dis* [Internet]. NIH Public Access; 2011 Feb [cited 2018 Jul 21];17(2):532–42. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20645323>
 248. Vallance BA, Chan C, Robertson ML, Finlay BB. Enteropathogenic and enterohemorrhagic *Escherichia coli* infections: emerging themes in pathogenesis and prevention. *Can J Gastroenterol* [Internet]. 2002 Nov [cited 2018 Aug 13];16(11):771–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12464970>
 249. Das S, Jayaratne R, Barrett KE. The Role of Ion Transporters in the Pathophysiology of Infectious Diarrhea. *Cell Mol Gastroenterol Hepatol* [Internet]. 2018 [cited 2018 Aug 13];6(1):33–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29928670>
 250. Fyderek K, Strus M, Kowalska-Duplaga K, Gosiewski T, Wedrychowicz A, Jedynak-Wasowicz U, et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. *World J Gastroenterol* [Internet]. 2009 Nov 14 [cited 2018 Aug 13];15(42):5287–94. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19908336>
 251. Schwerbrock NMJ, Makkink MK, van der Sluis M, Büller HA, Einerhand AWC, Sartor RB, et al. Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before

- and after induction of colitis by commensal bacteria. *Inflamm Bowel Dis* [Internet]. 2004 Nov [cited 2018 Aug 13];10(6):811–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15626900>
252. Johansson ME V, Gustafsson JK, Holmén-Larsson J, Jabbar KS, Xia L, Xu H, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. *Gut* [Internet]. 2014 Feb [cited 2018 Aug 13];63(2):281–91. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23426893>
 253. Fu J, Wei B, Wen T, Johansson MEV, Liu X, Bradford E, et al. Loss of intestinal core 1–derived O-glycans causes spontaneous colitis in mice. *J Clin Invest* [Internet]. 2011 Apr 1 [cited 2018 Aug 13];121(4):1657–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21383503>
 254. An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3–derived O-glycans. *J Exp Med* [Internet]. 2007 Jun 11 [cited 2018 Aug 20];204(6):1417–29. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17517967>
 255. Li H, Limenitakis JP, Fuhrer T, Geuking MB, Lawson MA, Wyss M, et al. The outer mucus layer hosts a distinct intestinal microbial niche. *Nat Commun* [Internet]. Nature Publishing Group; 2015 Sep 22 [cited 2018 Jan 10];6:8292. Available from: <http://www.nature.com/doifinder/10.1038/ncomms9292>
 256. Huang EY, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, et al. Using Corticosteroids to Reshape the Gut Microbiome. *Inflamm Bowel Dis* [Internet]. 2015 May [cited 2018 Aug 20];21(5):963–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25738379>
 257. Finnie IA, Dwarakanath AD, Taylor BA, Rhodes JM. Colonic mucin synthesis is increased by sodium butyrate. *Gut* [Internet]. 1995 Jan [cited 2018 Aug 20];36(1):93–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7890244>
 258. Shimotoyodome A, Meguro S, Hase T, Tokimitsu I, Sakata T. Short chain fatty acids but not lactate or succinate stimulate mucus release in the rat colon. *Comp Biochem Physiol A Mol Integr Physiol* [Internet]. 2000 Apr [cited 2018 Aug 20];125(4):525–31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10840229>
 259. Gaudier E, Jarry A, Blottière HM, De Coppet P, Buisine MP, Aubert JP, et al. Butyrate

- specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. [cited 2018 May 3]; Available from:
<https://www.physiology.org/doi/pdf/10.1152/ajpgi.00219.2004>
260. Leonel AJ, Teixeira LG, Oliveira RP, Santiago AF, Batista N V., Ferreira TR, et al. Antioxidative and immunomodulatory effects of tributyrin supplementation on experimental colitis. *Br J Nutr* [Internet]. 2013 Apr 20 [cited 2018 Aug 20];109(08):1396–407. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22906779>
 261. Zhao G, Nyman M, Åke Jönsson J. Rapid determination of short-chain fatty acids in colonic contents and faeces of humans and rats by acidified water-extraction and direct-injection gas chromatography. *Biomed Chromatogr* [Internet]. 2006 Aug [cited 2018 Nov 6];20(8):674–82. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16206138>
 262. Alipour M, Zaidi D, Valcheva R, Jovel J, Martínez I, Sergi C, et al. Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis. *J Crohn's Colitis* [Internet]. 2016 Apr [cited 2018 Oct 23];10(4):462–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26660940>
 263. Kasprzak A, Siodła E, Andrzejewska M, Szmeja J, Seraszek-Jaros A, Cofta S, et al. Differential expression of mucin 1 and mucin 2 in colorectal cancer. *World J Gastroenterol* [Internet]. 2018 Sep 28 [cited 2018 Oct 23];24(36):4164–77. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30271081>
 264. Johansson ME V, Larsson JMH, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci U S A* [Internet]. National Academy of Sciences; 2011 Mar 15 [cited 2018 Oct 16];108 Suppl 1(Suppl 1):4659–65. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20615996>
 265. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* [Internet]. NIH Public Access; 2016 [cited 2018 May 3];167(5):1339–1353.e21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27863247>
 266. Maaser C, Housley MP, Iimura M, Smith JR, Vallance BA, Finlay BB, et al. Clearance of

- Citrobacter rodentium Requires B Cells but Not Secretory Immunoglobulin A (IgA) or IgM Antibodies. Infect Immun [Internet]. 2004 Jun 1 [cited 2018 Oct 24];72(6):3315–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15155635>
267. Bry L, Brigl M, Brenner MB. CD4+-T-Cell Effector Functions and Costimulatory Requirements Essential for Surviving Mucosal Infection with Citrobacter rodentium. Infect Immun [Internet]. 2006 Jan 1 [cited 2018 Oct 24];74(1):673–81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16369024>
 268. An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3–derived O-glycans. J Exp Med [Internet]. 2007 Jun 11 [cited 2018 Oct 24];204(6):1417–29. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17517967>
 269. Robbe C, Capon C, Coddeville B, Michalski J-C. Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J [Internet]. Portland Press Ltd; 2004 Dec 1 [cited 2018 Oct 24];384(Pt 2):307–16. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15361072>
 270. Vieira ELM, Leonel AJ, Sad AP, Beltrão NRM, Costa TF, Ferreira TMR, et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem. Elsevier Inc.; 2012;23(5):430–6.
 271. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology [Internet]. 1992 Jul [cited 2018 Oct 24];103(1):51–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1612357>
 272. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci [Internet]. 1996 Nov [cited 2018 Oct 24];41(11):2254–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8943981>
 273. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, Zeides S, Braverman DZ. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol [Internet]. 1996 Apr [cited 2018 Oct 24];91(4):731–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8677939>

274. Guest JF, Kobayashi RH, Mehta V, Neidich G. Cost-effectiveness of using an extensively hydrolyzed casein formula containing *Lactobacillus rhamnosus* GG in managing infants with cow's milk allergy in the US. *Curr Med Res Opin* [Internet]. Taylor & Francis; 2018 Sep 2 [cited 2018 Dec 4];34(9):1539–48. Available from:
<https://www.tandfonline.com/doi/full/10.1080/03007995.2017.1400962>
275. Lenoir-Wijnkoop I, Nuijten MJC, Craig J, Butler CC. Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea. *Front Pharmacol* [Internet]. Frontiers; 2014 Feb 17 [cited 2018 Dec 4];5:13. Available from:
<http://journal.frontiersin.org/article/10.3389/fphar.2014.00013/abstract>
276. Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, et al. Prophylactic Use of a Probiotic in the Prevention of Colic, Regurgitation, and Functional Constipation. *JAMA Pediatr* [Internet]. American Medical Association; 2014 Mar 1 [cited 2018 Dec 4];168(3):228. Available from:
<http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/jamapediatrics.2013.4367>
277. Lenoir-Wijnkoop I, Gerlier L, Roy D, Reid G. The Clinical and Economic Impact of Probiotics Consumption on Respiratory Tract Infections: Projections for Canada. Arez AP, editor. *PLoS One* [Internet]. Public Library of Science; 2016 Nov 10 [cited 2018 Dec 4];11(11):e0166232. Available from: <http://dx.plos.org/10.1371/journal.pone.0166232>
278. Lenoir-Wijnkoop I, Gerlier L, Bresson J-L, Le Pen C, Berdeaux G. Public Health and Budget Impact of Probiotics on Common Respiratory Tract Infections: A Modelling Study. Foligne B, editor. *PLoS One* [Internet]. 2015 Apr 10 [cited 2018 Dec 4];10(4):e0122765. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25859849>
279. Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Aliment Pharmacol Ther* [Internet]. 2017 Aug [cited 2018 Dec 4];46(4):389–400. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/28653751>
280. Rivera-Chávez F, Lopez CA, Bäumlér AJ. Oxygen as a driver of gut dysbiosis. *Free Radic Biol Med* [Internet]. 2017 Apr [cited 2018 Dec 4];105:93–101. Available from:
<http://www.ncbi.nlm.nih.gov/pubmed/27677568>